At the Heart of Gene Therapy: Lexeo’s R. Nolan Townsend on Genetic Medicines for Cardiovascular Diseases and More — Episode 229

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with R. Nolan Townsend, MBA, CEO of Lexeo Therapeutics, a company developing gene therapies for cardiovascular diseases as well as CNS disorders including Alzheimer’s disease.

Lexeo recently announced a partnership to advance cardiac RNA therapeutics as well as $80 million in equity financing.

Mr. Townsend has been CEO of Lexeo Therapeutics since 2020. He previously held senior leadership roles at Pfizer, including President of Rare Disease for both North America and International markets, and began his career in healthcare investment banking at Lehman Brothers. He currently also serves on several boards, including Arbor Biotechnologies, the Biotechnology Innovation Organization (BIO) and the Martha’s Vineyard Museum. He is also a member of the New York City Economic Development Corporation’s Life Sciences Advisory Council.

Mr. Townsend received his MBA from the Harvard Business School and his Bachelor of Arts in Economics from the University of Pennsylvania.

Tune in to hear how Lexeo is shaping the future of genetic medicines under Mr. Townsend’s leadership.

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.